| Rituxan (rituximab) / Roche |
NCT02622503: A Study on Rheumatoid Arthritis Patients Treated With Rituximab |
|
|
| Completed | N/A | 81 | Europe | Rituximab | Hoffmann-La Roche | Rheumatoid Arthritis | 08/08 | 08/08 | | |
NCT02322801: Observational Safety Study of Rituximab in Patients Diagnosed With Rheumatoid Arthritis (RA) Who Did Not Respond Adequately to TNF-alpha Blocker |
|
|
| Completed | N/A | 209 | Europe | | Hoffmann-La Roche | Rheumatoid Arthritis | 11/11 | 11/11 | | |
NCT01075477: An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab) |
|
|
| Completed | N/A | 151 | Europe | rituximab [Mabthera/Rituxan] | Hoffmann-La Roche | Rheumatoid Arthritis | 12/11 | 12/11 | | |
NCT02564770: A Retrospective Chart Review of MabThera (Rituximab) Treatment in Rheumatoid Arthritis (RA) Participants in Australia |
|
|
| Completed | N/A | 167 | RoW | | Hoffmann-La Roche, Roche Products Pty Ltd (Australia) | Rheumatoid Arthritis | 02/12 | 02/12 | | |
NCT00963703: Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis |
|
|
| Completed | N/A | 15 | Canada | Rituximab | University of Manitoba, Hoffmann-La Roche | Rheumatoid Arthritis | 03/12 | 03/12 | | |
NCT01557348: An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor |
|
|
| Completed | N/A | 1239 | Canada, Europe, RoW | | Hoffmann-La Roche | Rheumatoid Arthritis | 03/12 | 03/12 | | |
|
NCT02507752: An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab |
|
|
| Completed | N/A | 94 | RoW | | Hoffmann-La Roche | Rheumatoid Arthritis | 06/12 | 06/12 | | |
NCT00844714: Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy |
|
|
| Completed | N/A | 20 | US | Rituxan | University of California, San Francisco, Genentech, Inc. | Endothelial Function, Rheumatoid Arthritis, Inflammation | 12/12 | 12/14 | | |
|
NCT01309282: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB) |
|
|
| Completed | N/A | 9 | Europe | | Hoffmann-La Roche | Rheumatoid Arthritis | 08/13 | 08/13 | | |
SUNSTONE, NCT00443443: A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy |
|
|
| Completed | N/A | 1026 | US | | Genentech, Inc., Biogen | Rheumatoid Arthritis | 09/13 | 09/13 | | |
NCT02699892: Study to Examine Efficacy and Safety of Rituximab in Participants With Rheumatoid Arthritis |
|
|
| Completed | N/A | 130 | RoW | Rituximab, MabThera | Hoffmann-La Roche | Rheumatoid Arthritis | 02/14 | 02/14 | | |
NCT01283399: An Observational Study of Rituximab in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis |
|
|
| Completed | N/A | 79 | RoW | | Hoffmann-La Roche | Rheumatoid Arthritis | 04/14 | 04/14 | | |
NCT01071798: An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis |
|
|
| Completed | N/A | 1653 | Europe | Rituximab, Mabthera, Rituxan | Hoffmann-La Roche | Rheumatoid Arthritis | 10/14 | 10/14 | | |
NCT01592292: An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy |
|
|
| Completed | N/A | 90 | RoW | Rituximab, Mabthera, Adalimumab, Etanercept, Infliximab | Hoffmann-La Roche | Rheumatoid Arthritis | 12/14 | 12/14 | | |
NCT01641952: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent |
|
|
| Completed | N/A | 505 | Europe | Rituximab, Mabthera | Hoffmann-La Roche | Rheumatoid Arthritis | 01/15 | 01/15 | | |
NCT01613599: An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis |
|
|
| Completed | N/A | 100 | US | Rituximab, Rituxan | Genentech, Inc. | Granulomatosis With Polyangiitis, Microscopic Polyangiitis | 07/15 | 04/17 | | |
NCT01613027: An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis |
|
|
| Completed | N/A | 135 | Europe | Rituximab, MabThera® | Hoffmann-La Roche | Rheumatoid Arthritis | 09/15 | 09/15 | | |
NCT01196780: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT) |
|
|
| Terminated | N/A | 1240 | Europe | | Hoffmann-La Roche | Rheumatoid Arthritis | 10/15 | 10/15 | | |
|
NCT01643928 / 2012-003223-38: Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04) |
|
|
| Completed | N/A | 185 | Canada, US, Europe, RoW | Rituximab-Pfizer (PF-05280586) x 3 courses, Rituximab-EU+ Rituximab-Pfizer x 2 Courses, Rituximab-US + Rituximab-Pfizer x 2 Courses | Pfizer | Rheumatoid Arthritis | 03/16 | 03/16 | | |
